These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 28089686)

  • 1. Simulations of Cytochrome P450 3A4-Mediated Drug-Drug Interactions by Simple Two-Compartment Model-Assisted Static Method.
    Iga K; Kiriyama A
    J Pharm Sci; 2017 May; 106(5):1426-1438. PubMed ID: 28089686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic and Static Simulations of Fluvoxamine-Perpetrated Drug-Drug Interactions Using Multiple Cytochrome P450 Inhibition Modeling, and Determination of Perpetrator-Specific CYP Isoform Inhibition Constants and Fractional CYP Isoform Contributions to Victim Clearance.
    Iga K
    J Pharm Sci; 2016 Mar; 105(3):1307-17. PubMed ID: 26886336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of Two-Compartment Model-Assisted and Static Overall Inhibitory-Activity Method for Prediction of Drug-Drug Interaction.
    Iga K; Kiriyama A
    Biol Pharm Bull; 2017 Dec; 40(12):2024-2037. PubMed ID: 28993551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
    Umehara K; Huth F; Jin Y; Schiller H; Aslanis V; Heimbach T; He H
    Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions.
    Guo H; Liu C; Li J; Zhang M; Hu M; Xu P; Liu L; Liu X
    J Pharm Sci; 2013 Aug; 102(8):2819-36. PubMed ID: 23760985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
    Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
    Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simulation of Metabolic Drug-Drug Interactions Perpetrated by Fluvoxamine Using Hybridized Two-Compartment Hepatic Drug-Pool-Based Tube Modeling and Estimation of In Vivo Inhibition Constants.
    Iga K
    J Pharm Sci; 2015 Oct; 104(10):3565-77. PubMed ID: 26099559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-Property Relationships and Machine Learning Models for Addressing CYP3A4-Mediated Victim Drug-Drug Interaction Risk in Drug Discovery.
    Hu B; Zhou X; Mohutsky MA; Desai PV
    Mol Pharm; 2020 Sep; 17(9):3600-3608. PubMed ID: 32794756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information.
    Ohno Y; Hisaka A; Ueno M; Suzuki H
    Clin Pharmacokinet; 2008; 47(10):669-80. PubMed ID: 18783297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover.
    Qian CQ; Zhao KJ; Chen Y; Liu L; Liu XD
    Eur J Pharm Sci; 2019 Jun; 134():194-204. PubMed ID: 31047967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of a Physiologically Based Pharmacokinetic Model for Quantitative Prediction of Drug-Drug Interactions via CYP3A4 and Estimation of the Intestinal Availability of CYP3A4 Substrates.
    Mano Y; Sugiyama Y; Ito K
    J Pharm Sci; 2015 Sep; 104(9):3183-93. PubMed ID: 26045365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical assessment of gepotidacin (GSK2140944) as a victim and perpetrator of drug-drug interactions via CYP3A metabolism and transporters.
    Barth A; Perry CR; Shabbir S; Zamek-Gliszczynski MJ; Thomas S; Dumont EF; Brimhall DB; Nguyen D; Srinivasan M; Swift B
    Clin Transl Sci; 2023 Apr; 16(4):647-661. PubMed ID: 36642822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative evaluation of drug-drug interaction potentials by in vivo information- guided prediction approach.
    Chen F; Hu ZY; Jia WW; Lu JT; Zhao YS
    Curr Drug Metab; 2014; 15(8):761-6. PubMed ID: 25705907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of Drug-Drug Interactions After Esketamine Intranasal Administration Using a Physiologically Based Pharmacokinetic Model.
    Willemin ME; Zannikos P; Mannens G; de Zwart L; Snoeys J
    Clin Pharmacokinet; 2022 Aug; 61(8):1115-1128. PubMed ID: 35579824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Generic Model for Quantitative Prediction of Interactions Mediated by Efflux Transporters and Cytochromes: Application to P-Glycoprotein and Cytochrome 3A4.
    Tod M; Goutelle S; Bleyzac N; Bourguignon L
    Clin Pharmacokinet; 2019 Apr; 58(4):503-523. PubMed ID: 30194612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative Analyses of the Influence of Parameters Governing Rate-Determining Process of Hepatic Elimination of Drugs on the Magnitudes of Drug-Drug Interactions via Hepatic OATPs and CYP3A Using Physiologically Based Pharmacokinetic Models.
    Yoshikado T; Maeda K; Kusuhara H; Furihata KI; Sugiyama Y
    J Pharm Sci; 2017 Sep; 106(9):2739-2750. PubMed ID: 28495568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models.
    Yamada M; Inoue SI; Sugiyama D; Nishiya Y; Ishizuka T; Watanabe A; Watanabe K; Yamashita S; Watanabe N
    Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-drug interaction prediction of ziritaxestat using a physiologically based enzyme and transporter pharmacokinetic network interaction model.
    Perrier J; Gualano V; Helmer E; Namour F; Lukacova V; Taneja A
    Clin Transl Sci; 2023 Nov; 16(11):2222-2235. PubMed ID: 37667518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.
    Marzolini C; Rajoli R; Battegay M; Elzi L; Back D; Siccardi M
    Clin Pharmacokinet; 2017 Apr; 56(4):409-420. PubMed ID: 27599706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Trial Data-Driven Risk Assessment of Drug-Drug Interactions: A Rapid and Accurate Decision-Making Tool.
    Yuan T; Bi F; Hu K; Zhu Y; Lin Y; Yang J
    Clin Pharmacokinet; 2024 Aug; 63(8):1147-1165. PubMed ID: 39102093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.